Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Goldman says rotation driven by positioning, not fundamentals
• InterContinental Hotels Group (IHG:LN) (IHG) PT Raised to $145 at Deutsche Bank